185 related articles for article (PubMed ID: 7686188)
1. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.
Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH
J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
[TBL] [Abstract][Full Text] [Related]
3. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
4. Histologic and immunophenotypic features prior to transformation in patients with transformed cutaneous T-cell lymphoma: is CD25 expression in skin biopsy samples predictive of large cell transformation in cutaneous T-cell lymphoma?
Stefanato CM; Tallini G; Crotty PL
Am J Dermatopathol; 1998 Feb; 20(1):1-6. PubMed ID: 9504661
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy.
Stadler R; Otte HG
Recent Results Cancer Res; 1995; 139():391-401. PubMed ID: 7597306
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
7. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
8. [Combination therapy with interferon alfa 2a and PUVA in cutaneous T-cell lymphoma].
Otte HG; Herges A; Stadler R
Hautarzt; 1992 Nov; 43(11):695-9. PubMed ID: 1468931
[TBL] [Abstract][Full Text] [Related]
9. In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy.
Celerier P; Fleischmann M; Basset-Seguin N; Thill L; Bureau B; Litoux P; Dréno B
Arch Dermatol; 1993 Sep; 129(9):1136-40. PubMed ID: 8103318
[TBL] [Abstract][Full Text] [Related]
10. [Interferon-alpha in cutaneous T-cell lymphoma].
Knobler R
Wien Med Wochenschr; 1993; 143(16-17):435-7. PubMed ID: 8273368
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
12. Role of extracorporeal photochemotherapy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma.
Fimiani M; Rubegni P; De Aloe G; Andreassi L
J Am Acad Dermatol; 1999 Sep; 41(3 Pt 1):502-3. PubMed ID: 10459134
[No Abstract] [Full Text] [Related]
13. Interferons for cutaneous T-cell lymphoma monotherapy or combination with PUVA.
Roenigk HH; Kuzel T; Rosen S
Australas J Dermatol; 1993; 34(1):13-5. PubMed ID: 8240181
[No Abstract] [Full Text] [Related]
14. Correlations of unique clinical, immunotypic, and histologic findings in cutaneous gamma/delta T-cell lymphoma.
Heald P; Buckley P; Gilliam A; Perez M; Knobler R; Kacinski B; Edelson R
J Am Acad Dermatol; 1992 May; 26(5 Pt 2):865-70. PubMed ID: 1377210
[TBL] [Abstract][Full Text] [Related]
15. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
16. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
[TBL] [Abstract][Full Text] [Related]
18. Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas.
Dreno B; Fleischmann M; Valard S; Godefroy W; Bureau B; Stadler JF; Litoux P
Br J Dermatol; 1992 Apr; 126(4):320-3. PubMed ID: 1349233
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids.
Knobler RM; Trautinger F; Radaszkiewicz T; Kokoschka EM; Micksche M
J Am Acad Dermatol; 1991 Feb; 24(2 Pt 1):247-52. PubMed ID: 2007670
[TBL] [Abstract][Full Text] [Related]
20. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas.
Dréno B
Stem Cells; 1993 Jul; 11(4):269-75. PubMed ID: 8401250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
